OriTIL-003 / Oricell - LARVOL DELTA

AN EXPLORATORY PILOT TRIAL EVALUATING TUMOR INFILTRATING LYMPHOCYTES THERAPY ON RELAPSED OSTEOSARCOMA (CTOS 2021) - "Some of them were treated with second-line off-label targeted therapy such as anlotinib or apatinib, or anti-PD-1 antibody...Our study results provide evidence that autologous TILs infusion therapy, combined with non-myeloablative lymphodepletion with cyclophosphamide and fludarabine, and accompanied by high dose IL-2 infusion, is safe and holds promising antitumor potential. Current immune oncology approaches are not yet effective in osteosarcoma, and pulmonary metastases in osteosarcoma remain the major cause of cancer related mortality. Ligon et all presented data which supported that osteosarcoma PMs are more highly infiltrated by immune cells compared with primary tumors. Notably, tumors that demonstrate increased CD8 T cell infiltration and decreased PD-L1 expression were associated with improved PFS, suggesting that even in these relatively cold tumors the degree of immune response may influence the patient’s outcome."

IO biomarker • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Immune Modulation • Inflammation • Leukopenia • Neutropenia • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Thrombocytopenia • CD8 • PD-L1

An Exploratory Clinical Study of TILs in the Treatment of Recurrent / Refractory Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P1; N=15; Not yet recruiting; Sponsor: Shanghai OriginCell Therapeutics Co., Ltd.

Clinical • New P1 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor